NYAS Conferences
New York Academy of Sciences
left end
Search
divider divider feedback right end
Annals of the New York Academy of Sciences Annals of the New York Academy of Sciences login

Main

Browse Volumes

Forthcoming Volumes

Annals PrePrints

Annals Extra

E-mail Alerts

Subscriptions & Orders

New Proposals

Author Guidelines

About Annals

Help

Get free Annals volume as a NYAS member: http://www.nyas.org/annalsreaderhw
Issue 1005 coverImmunology of Diabetes II: Pathogenesis from Mouse to Man Volume 1005 published November 2003
Ann. N.Y. Acad. Sci. 1005: 138 (2003). doi: 10.1196/annals.1288.015
Copyright © 2003 by the New York Academy of Sciences
description | purchase volume purchase this volume

This Volume
Table of Contents
Description
This Article
Full Text
Full Text (PDF)
Services
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Citing Articles
Citing Articles via HighWire
Citing Articles via Google Scholar
Google Scholar
Articles by ITKIN-ANSARI, P.
Articles by LEVINE, F.
Search for Related Content
PubMed
PubMed Citation
Articles by ITKIN-ANSARI, P.
Articles by LEVINE, F.
Cell-Based Therapies for Diabetes: Progress towards a Transplantable Human ß Cell Line

PAMELA ITKIN-ANSARI, IFAT GERON, ERGENG HAO, CARLA DEMETERCO, BJORN TYRBERG AND FRED LEVINE

Cancer Center, University of California, San Diego, La Jolla, California, USA

Address for correspondence: Dr. Fred Levine, Cancer Center, UCSD School of Medicine-0912, La Jolla, CA 92093-0912. Voice: 858-822-2039; fax: 858-822-4181.
flevine{at}ucsd.edu
Ann. N.Y. Acad. Sci. 1005: 138-147 (2003).

Achieving normoglycemia is the goal of diabetes therapy. Potentially, there are many ways to achieve this goal, including transplantation of cells exhibiting glucose-responsive insulin secretion. However, to be applicable to the large number of people who might benefit from ß cell replacement, an unlimited supply of ß cells must be found. To address this problem, we have been developing cell lines from the human endocrine pancreas. In one case, a cell line, ßlox5, has been developed from human islets that can be induced under some circumstances to differentiate into functional ß cells exhibiting appropriate glucose-responsive insulin secretion. Inducing differentiation is complex, requiring the activation of multiple signaling pathways, including those downstream of those involved in cell-cell contact and the glucagon-like peptide-1 receptor. In addition, transfer of the PDX-1 gene is also necessary to render the cells competent for differentiation. However, it is clear that many other genes are involved in maintaining the commitment of ßlox5 cells towards the ß cell lineage. Understanding the complement of genes required to establish and maintain a ß cell lineage commitment would be enormously helpful in efforts to develop a cell line that can be used for ß cell replacement therapies. Here, we provide further information on the characteristics of cell lines that we have developed from the human pancreas that are relevant to the development of a ß cell replacement therapy for diabetes.

Key Words: ß cell • ßlox5 • diabetes • islets • pancreas • therapy • transplantation




This article has been cited by other articles:


Home page
Ann. N. Y. Acad. Sci.Home page
N. BABAYA, M. NAKAYAMA, and G. S. EISENBARTH
The Stages of Type 1A Diabetes
Ann. N.Y. Acad. Sci., June 1, 2005; 1051(1): 194 - 204.
[Abstract] [Full Text] [PDF]



footerLeft footerRight